🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin C
175 mg (292% DV)
10 mg (67% DV)
✅ Within RDA (0.9× RDA of 11 mg) 📚 258 studies (Tier A: 6, B: 134)
RDA 11mg This product: 10mg UL 40mg
12 mcg (200% DV)
📊 5.0× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.012mg
Iron
75 mg (417% DV)
1 mg (250% DV)
✅ 2.5× RDA — within safe limits 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 1mg UL 1.0mg
Succinic Acid
150 mg

Other Ingredients

Other Ingredients (Red Iron Tablets) Other Ingredients (Purple Inert Tablets)

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (99% of products) Structure/Function (83% of products) Nutrient (54% of products)

Target Groups

Adult (18 - 50 Years) Pregnant Women Lactating

Product Information

📋 Directions for Use

Dosage and Administration: Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7 Tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple inert tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple inert tablet daily for 7 days. After 28 tablets have been taken a new course maybe started if prescribed.

⚠️ Warnings & Precautions

Contraindications: FeRiva 21/7 is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.

Warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Precautions: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.

Adverse Reactions: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

Keep out of reach of children.

🧪 Formulation Notes

Description: FeRiva 21/7 tablets for oral administration is a 28-day iron supplement regiment that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped inert tablets. Each red, oval-shaped iron tablet is debossed with "21" and "7" separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped inert tablet is blank on both sides of the tablet.

Purple Inert Tablets do not contain any vitamins, minerals or other dietary ingredients. Please see other ingredients section below for the listing of the inert ingredients.

Indications: FeRiva 21/7 is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.

Additional Information

RX Only

How Supplied: FeRiva 21/7 tablets blister pack (75854+318-28) contains 21 red iron tablets and 7 purple inert tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.

Store betweed 20 degrees - 25 degrees C (68 degrees - 77 degrees F).

Product Details

DSLD Entry Date 2020-11-21
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 239383
Data Updated 2026-04-11

Research Evidence

371 Research Sources
54 Avg Quality Score
148 Meta Analysis
82 Systematic Review
71 Rct
62 Clinical Trial
2 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Other
1 Openfda Safety
A Vitamin C supplementation in pregnancy
Meta Analysis The Cochrane database of systematic reviews 2015
A Vitamin C supplementation for the primary prevention of cardiovascular disease
Systematic Review The Cochrane database of systematic reviews 2017
A Vitamin C for preventing and treating the common cold
Meta Analysis The Cochrane database of systematic reviews 2013
A Vitamin C for preventing and treating pneumonia
Meta Analysis The Cochrane database of systematic reviews 2013
A Vitamin E supplementation in pregnancy
Meta Analysis The Cochrane database of systematic reviews 2015
A Vitamin C supplementation for prevention and treatment of pneumonia
Meta Analysis The Cochrane database of systematic reviews 2020
A Vitamin C supplementation for prevention and treatment of pneumonia
Systematic Review The Cochrane database of systematic reviews 2021
A Nutritional interventions for preventing and treating pressure ulcers
Meta Analysis The Cochrane database of systematic reviews 2024
A Does Vitamin C Supplementation Provide a Protective Effect in Periodontal Health? A Systematic Review and Meta-Analysis
Meta Analysis International journal of molecular sciences 2024
A Circulating vitamin C concentration and risk of cancers: a Mendelian randomization study
Meta Analysis BMC medicine 2021
View all evidence for Vitamin C →

Compare Similar Products

View all Vitamin C products →